iPhone vs Android: Digital Silk Publishes 2024 User Insights Comparing U.S. Device Habits
Digital Silk Publishes 2024 User Insights Comparing U.S. Device Habits
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10732/258856_750fcbb1e4279bee_001full.jpg
Based on data from multiple sources including Statista, CIRP, and Experian, the report explores how platform preferences are influencing digital marketing strategy. Notably, iPhone users accounted for nearly 58% of U.S. smartphone subscribers as of Q1 2024, while Android users were more dominant globally.
Key Findings from the Report
The report aims to support businesses in making platform-specific decisions by highlighting differences such as:
iPhone users have a higher average income and tend to spend more on mobile apps
Android users show greater platform diversity and higher global market share
Apple users exhibit stronger brand loyalty, with over 90% planning to stay with iOS
Android dominates in regions like Africa and Asia, where cost and customization are driving factors
Strategic Implications for Mobile Marketing
"Understanding platform-specific behaviors can help businesses make more informed decisions about mobile experiences, app development, and ad targeting," said Gabriel Shaoolian, CEO of Digital Silk. "These insights can potentially support stronger ROI in device-specific campaigns."
With over 90% of internet users accessing the web through mobile devices, brands are increasingly prioritizing responsive design and user-specific strategies. Digital Silk's report is intended to assist marketing teams in evaluating where their audiences are-and how they behave.
The full article, including data sources and graphs, is available here: iPhone vs Android User Stats
About Digital Silk
Digital Silk is an award-winning Miami Digital Marketing Agency focused on growing brands online. With a team of seasoned experts, we create digital experiences through strategic branding, custom web design, and digital marketing services to help improve visibility and support engagement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
Key Points Income-focused investors seeking reliable dividends and a stable company can consider investing in telecommunications giant Verizon. AT&T's disciplined financial management is supporting its solid 4.1% dividend yield. AbbVie's ability to thrive post-Humira, combined with a 53-year history of dividend growth, makes it a smart buy now. 10 stocks we like better than Verizon Communications › It has been a volatile year for the U.S. markets, with many stocks experiencing impressive highs and sharp lows. Investing in such a turbulent environment may feel daunting for retail investors. However, dividend-paying stocks can help generate substantial passive income even amid market fluctuations. With the correct picks, investors can generate a steady dividend income even with a relatively modest investment. For instance, investing $2,000 each in Verizon Communications (NYSE: VZ), AT&T (NYSE: T), and AbbVie (NYSE: ABBV) will generate a total of $282.60 in passive income annually. Here's how the dividend income breaks down: With a 6.5% yield, $2,000 invested in Verizon will generate $130.20 in annual dividends. With a 4.1% yield, $2,000 invested in AT&T will generate $82.40 in annual dividends. With a 3.5% yield, $2,000 invested in AbbVie will generate $70 in annual dividends. These stocks are not only reliable dividend payers, but also boast strong business models and a rich and durable history of returning value to shareholders. Verizon Communications giant Verizon offers investors a sustainable 6.5% dividend yield, which translates to $2.71 annually per share, all backed by solid business fundamentals. It has raised its dividend for 18 consecutive years. Verizon's strong financial results underline the stability of its dividend policy. The company delivered its highest-ever quarterly adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $12.6 billion in the first quarter of fiscal 2025 (ending March 31). Free cash flow was $3.6 billion. With a dividend payout ratio of 64.2%, there are enough earnings to cover the dividend. The company's convergence strategy, which integrates its wireless and wireline networks (including 5G and fiber-optic networks) to create comprehensive connectivity solutions, has proven successful. This has helped reduce customer churn by 40% to 50% for both mobility and fiber products. A sticky customer base translates into predictable cash flows. Besides retaining existing customers, the company is also rapidly acquiring new clients. Verizon added 339,000 broadband customers and 308,000 fixed wireless customers in the first quarter. The company aims to achieve a goal of 100 million premises with fiber and fixed wireless access following the completion of its pending Frontier acquisition. Besides telecommunication services, Verizon built a robust adjacent services business (including discounted streaming services and other subscriptions, insurance products, and financial services) expected to clock an annual run rate of $2 billion by the end of 2025. The business also boasts mid-30s margins. Management is guiding for 2% to 3.5% adjusted EBITDA growth and free cash flows of $17.5 billion to $18.5 billion in 2025. This provides the required cushion for dividend sustainability. Hence, for investors seeking to earn passive income from high-quality companies, Verizon appears to be a smart buy now. AT&T Telecommunications giant AT&T is offering a solid 4.1% yield, which translates to $1.11 per share annually. The dividend also appears well-covered with a 68.1% dividend payout ratio, implying that the company also has the flexibility to increase dividends in the coming years. AT&T expects to resume share buybacks in the second quarter of fiscal 2025 as part of a $10 billion repurchase program, with at least $3 billion completed by the end of fiscal 2025, and the remainder allocated for fiscal 2026. AT&T has also been increasingly focusing on financial discipline. Since 2020, the company reduced its net debt by $32 billion. It ended the first quarter of fiscal 2025 with a net debt-to-adjusted EBITDA ratio of 2.63, lower than the 2.68 ratio at the end of fiscal 2024. In Q1, the company's revenues increased 2% to $30.6 billion, net income rose 23.6% year over year to $4.7 billion, and free cash flow increased 10.7% year over year to $3.1 billion. These numbers demonstrate AT&T's ability to fund its dividend policy sustainably while maintaining sufficient financial flexibility to invest in growth initiatives and repurchase shares. AT&T also has exceptional fiber and wireless businesses, both of which are relatively recession-resistant. The company is currently operating the largest fiber network in the U.S. and expects to hit 30 million fiber locations by mid-2025 and 50 million by 2029. This expansion is already driving strong customer growth, with 261,000 fiber net additions in Q1 alone. Additionally, the company's wireless network modernization and fixed wireless expansion contributed to a customer count increase of 181,000 during Q1. AT&T is also benefiting by bundling its services, creating stickier and more profitable customer relationships. AT&T Fiber and wireless services have 15% higher lifetime values than stand-alone customers. For income investors seeking defensive dividend growth, this transformed telecommunications player is an appealing pick now. AbbVie AbbVie also offers an impressive yield of 3.52% with an annual payout of $6.56 per share. With its history of increasing dividends for 53 consecutive years (including its Abbott Laboratories heritage), AbbVie sports the prestigious Dividend King status. When AbbVie lost the patent protection for its blockbuster immunology drug Humira in 2023, many investors were concerned about the sustainability of its dividend policy. However, the company has successfully reduced its over-reliance on Humira and continues to thrive even after the dreaded patent cliff. Humira's sales have fallen more than expected, decreasing by 49.5% year over year to $1.1 billion in Q1 of fiscal 2025. However, its next-generation immunology drugs Skyrizi and Rinvoq are showing impressive results, generating a combined $5.1 billion, a substantial 65% year-over-year increase. Management now expects these two drugs to generate $31 billion in combined sales by 2027, surpassing Humira's peak sales of $20.7 billion. In addition to immunology, AbbVie has successfully diversified into areas such as neuroscience, oncology, and aesthetics. The company is also focusing on strategic investments, including a $350 million obesity partnership with Gubra and plans for a $2.1 billion acquisition of CAR-T therapy developer Capstan Therapeutics. These deals will position AbbVie in several high-growth areas. Recently, however, AbbVie announced that the acquired in-process research and development (IPR&D) and milestone expenses have negatively affected its second-quarter earnings guidance. While these represent a short-term challenge, the deals can prove to be major growth drivers in the long run. With AbbVie proving its capability to navigate major patent cliffs while growing its dividend, I think the stock is worth considering in 2025. Should you invest $1,000 in Verizon Communications right now? Before you buy stock in Verizon Communications, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Verizon Communications wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
an hour ago
- Globe and Mail
3 Top Growth Stocks to Buy in the Second Half of 2025
Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off handsomely. Vertex Pharmaceuticals is expanding into new indications. 10 stocks we like better than Vertex Pharmaceuticals › For decades, Jim McKay introduced ABC's Wide World of Sports with a memorable phrase, "The thrill of victory, and the agony of defeat." McKay's words could apply to many investors in the first half of this year. There have been periods of victory -- and periods of defeat. Of course, the level of victory and defeat investors experienced depended on which stocks they owned. If you want greater chances of winning going forward, the stocks you pick will make a huge difference. Which stocks should you consider? Here are three top growth stocks to buy in the second half of 2025. 1. Alibaba Group Holding Wall Street loves Alibaba Group Holding (NYSE: BABA). Of the 40 analysts surveyed by LSEG in July, 37 rated the stock as a "buy" or a "strong buy." The three outliers recommended holding Alibaba. The consensus 12-month price target reflects an upside potential of roughly 40%. I'm not always on the same page as Wall Street analysts, but I agree with the upbeat views about Alibaba. For one thing, you can't even spell Alibaba without A and I. "Lbaba" just doesn't have the same ring to it. Alibaba is an artificial intelligence (AI) juggernaut in China. Its Alibaba Cloud unit commands 36% of the Chinese cloud infrastructure market, almost twice the market share of its nearest rival. Revenue from Alibaba Cloud's AI-related products has grown by triple-digit percentages for seven consecutive quarters. The company also operates China's leading e-commerce platform. Alibaba's Taobao and Tmall online shopping sites continue to deliver solid revenue growth, and AI is helping improve the user experience on the platforms. But the main reason I like Alibaba is its valuation. The stock trades at a forward earnings multiple of only 10.3. That's dirt cheap for a tech giant that raked in $137.3 billion in revenue and $17.4 billion in profits in its last fiscal year. 2. Meta Platforms Meta Platforms (NASDAQ: META) could be an underappreciated leader in AI. It's not a pure-play AI company like OpenAI. It's not a cloud titan like Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), and Alphabet 's (NASDAQ: GOOG)(NASDAQ: GOOGL) Google. However, Meta is making a huge bet on AI that I suspect will pay off handsomely. That wager is already paying off in some ways. For example, AI is helping Meta improve its recommendation models. The company has seen a 5% higher conversion rate on Reels in the latest quarter. Over the last six months, Meta's recommendation system improvements have led to a 7% increase in user time spent on Facebook and 6% on Instagram. More time on these social media apps translates to higher advertising revenue for Meta. AI-powered business messaging presents a tremendous growth opportunity for the company. Businesses in developing nations such as Thailand and Vietnam use Meta's messaging apps heavily to communicate with customers. With AI, this model could be deployed in the U.S. and other major markets. Perhaps the most intriguing arena for Meta, though, is in AI devices. The company is already a leader in smart glasses thanks to its Ray-Ban Meta AI glasses. Its Quest virtual reality headsets remain highly popular with users. I think Meta could be one of the biggest players in a potentially massive AI device market over the next few years. 3. Vertex Pharmaceuticals Not every great growth stock that I recommend buying in the second half of 2025 is focused heavily on AI. Vertex Pharmaceuticals (NASDAQ: VRTX) is a drugmaker with terrific growth prospects. So far in Vertex's history, cystic fibrosis (CF) has been the company's primary focus. That's worked out quite well for the big biotech innovator. Vertex markets the only therapies that treat the underlying cause of CF. Its latest CF drug, Alyftrek, offers the most convenient dosing in its lineup and will almost certainly become a blockbuster quickly. However, Vertex has expanded its horizons to other therapeutic areas. Casgevy, the first approved CRISPR gene-editing therapy, targets two rare blood disorders -- sickle cell disease and transfusion-dependent beta-thalassemia. Earlier this year, Journavx became the first new class of pain medication approved by the U.S. Food and Drug Administration in more than two decades. As a powerful pain drug that isn't an opioid, I expect this new product will become another huge winner for Vertex. And there are potentially more big winners on the way. Vertex's pipeline features three other drugs in late-stage clinical testing. Inaxaplin targets APOL1-mediated kidney disease. Povetacicept's first targeted indication is chronic kidney disease IgA nephropathy. Zimislicel holds the potential to cure severe type 1 diabetes. I like the chances of success for all three programs. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, Meta Platforms, Microsoft, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Vertex Pharmaceuticals. The Motley Fool recommends Alibaba Group and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
National Post
an hour ago
- National Post
Colby Cosh: The lifelike nature of artificial intelligence
Article content On Tuesday a Harvard artificial-intelligence researcher, Keyon Vafa, published a short tweet-thread about a new paper looking at how some types of high-performing intelligence algorithms are behaving under the hood. If you're interested in the implications of AI progress, this paper is instructive even if you don't fully understand it, and, yes, that is tantamount to a confession on my part. (And, as the old joke goes, if you're not interested in the implications of AI progress, rest assured that AI progress is interested in you.) Article content Article content For academics like Vafa and his colleagues, AI has a pervasive 'black box' issue that is part of why it inspires fear and confusion. We have learned how to make computers mimic intelligence quite convincingly, and sooner than almost anyone imagined, by applying previously unfathomable amounts of brute computing power. But our ability to understand how these thinking objects are thinking is often limited. Article content Article content If you don't understand anything at all about the Vafa paper, the thing to notice about it is that it is fundamentally experimental. The research approach is oddly like a biologist's, like somebody who studies wombats by rounding up a bunch of wombats and observing wombat behaviour. The team 'teaches' an AI algorithm to perform intellectual task X to near-perfection by giving it verbal instructions and data (in plain English), and then has to figure out 'How did it actually do that?' using statistical inference. It's the choice of task X that makes this paper most intriguing. Anybody educated enough to still be reading a newspaper probably knows the basics of how the human understanding of planetary orbits evolved. In classical antiquity, the prevailing assumption was that the planets orbited the Earth in circular paths. Well before the birth of Jesus, astronomers were already good at predicting the movements of the planets on the basis of this false model. The planets sometimes apparently move backwards in the sky, so an unmodified 'fixed Earth' + 'perfectly circular paths' model couldn't do the job on its own: to make accurate predictions, astronomers had to add other circular motions-within-motions, called 'deferents' and 'epicycles,' to the basic circular-orbit picture. Article content Article content Well, fast-forward a dozen centuries, and along come Copernicus asking 'What if Earth isn't at the centre after all?'; Kepler asking 'What if the orbits aren't circular, but elliptical?'; and Newton, who got to the bottom of the whole thing by introducing the higher-level abstraction of gravitational force. Bye-bye epicycles. Article content None of these intellectual steps, mind you, added anything to anyone's practical ability to predict planetary motions. Copernicus's model took generations to be accepted for this reason (along with the theological/metaphysical objections to the Earth not being at the centre of the universe): it wasn't ostensibly as sophisticated or as powerful as the old reliable geocentric model. But you can't get to Newton, who found that the planets and earthbound objects are governed by the same elegant and universal laws of motion, without Copernicus and Kepler. Article content Which, in 2025, raises the question: could a computer do what Newton did? Vafa's research group fed orbital data to AIs and found that they could correctly behave like ancient astronomers: make dependable extrapolations about the future movements of real planets, including the Earth. This raises the question whether the algorithms in question generate their successful orbital forecasts by somehow inferring the existence of Newtonian force-abstractions. We know that 'false,' overfitted models and heuristics can work for practical purposes, but we would like AIs to be automated Newtons if we are going to live with them. We would like AIs to discover new laws and scientific principles of very high generality and robustness that we filthy meatbags haven't noticed yet.
